亚洲患者中药物诱导的慢加急性肝衰竭
在亚太肝病研究学会慢加急性肝衰竭研究联盟前瞻性队列的3132例患者中,329例(10.5%)为药物诱导,以补充与替代药物(71.7%)和抗结核联合治疗药物(27.3%)最常见。药物诱导组90天死亡率46.5%,高于非药物诱导组的38.8%(P = 0.007);动脉乳酸(P < 0.001)和总胆红素(P = 0.008)为死亡预测因素。
要点
- 药物是亚太地区慢加急性肝衰竭的重要可识别病因,以补充与替代药物和抗结核药为主。
- 药物诱导组90天死亡率为46.5%,非药物诱导组为38.8%(P = 0.007)。
- 动脉乳酸(P < 0.001)和总胆红素(P = 0.008)是药物诱导慢加急性肝衰竭死亡的预测因素。
核心结论
- 药物是亚太国家慢加急性肝衰竭的重要可识别病因,以补充与替代药物为主,其次为抗结核药物。
- 肝性脑病、胆红素、血尿素、乳酸和国际标准化比值可预测药物诱导慢加急性肝衰竭患者的死亡。
研究设计与样本
- 从亚太肝病研究学会慢加急性肝衰竭研究联盟数据库的前瞻性慢加急性肝衰竭患者队列中识别药物作为诱因。
- 药物作为诱因需排除已知病因,并存在暴露与失代偿之间的时间关联。
- 共纳入3132例慢加急性肝衰竭患者,其中药物诱导329例(10.5%),非药物诱导2803例(89.5%)。
- 药物诱导组平均年龄47岁,男性占65%。
主要发现
- 药物诱导组中最常见诱因为补充与替代药物(71.7%),其次为抗结核联合治疗药物(27.3%)。
- 药物诱导组基础肝病常见为酒精性肝病(28.6%)、隐源性肝病(25.5%)和非酒精性脂肪性肝炎(16.7%)。
- 药物诱导组临床特征包括黄疸(100%)、腹水(88%)、肝性脑病(46.5%),MELD评分为30.2,Child-Turcotte-Pugh评分为12.1。
- 药物诱导组90天总死亡率为46.5%,非药物诱导组为38.8%,差异有统计学意义(P = 0.007)。
- Cox回归模型显示动脉乳酸(P < 0.001)和总胆红素(P = 0.008)为死亡的预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Acute insults from viruses, infections, or alcohol are established causes of decompensation leading to acute-on-chronic liver failure (ACLF). Information regarding drugs as triggers of ACLF is lacking. We examined data regarding drugs producing ACLF and analyzed clinical features, laboratory characteristics, outcome, and predictors of mortality in patients with drug-induced ACLF. METHODS: We identified drugs as precipitants of ACLF among prospective cohort of patients with ACLF from the Asian Pacific Association of Study of Liver (APASL) ACLF Research Consortium (AARC) database. Drugs were considered precipitants after exclusion of known causes together with a temporal association between exposure and decompensation. Outcome was defined as death from decompensation. RESULTS: Of the 3,132 patients with ACLF, drugs were implicated as a cause in 329 (10.5%, mean age 47 years, 65% men) and other nondrug causes in 2,803 (89.5%) (group B). Complementary and alternative medications (71.7%) were the commonest insult, followed by combination antituberculosis therapy drugs (27.3%). Alcoholic liver disease (28.6%), cryptogenic liver disease (25.5%), and non-alcoholic steatohepatitis (NASH) (16.7%) were common causes of underlying liver diseases. Patients with drug-induced ACLF had jaundice (100%), ascites (88%), encephalopathy (46.5%), high Model for End-Stage Liver Disease (MELD) (30.2), and Child-Turcotte-Pugh score (12.1). The overall 90-day mortality was higher in drug-induced (46.5%) than in non-drug-induced ACLF (38.8%) (P = 0.007). The Cox regression model identified arterial lactate (P < 0.001) and total bilirubin (P = 0.008) as predictors of mortality. DISCUSSION: Drugs are important identifiable causes of ACLF in Asia-Pacific countries, predominantly from complementary and alternative medications, followed by antituberculosis drugs. Encephalopathy, bilirubin, blood urea, lactate, and international normalized ratio (INR) predict mortality in drug-induced ACLF.
引用
- Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-Induced Acute-on-Chronic Liver Failure in Asian Patients. Am J Gastroenterol. 2019. PMID: 31021832. doi:10.14309/ajg.0000000000000201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。